Evidence map›Paper›PMID 30275547›Full record

ArticleScientific reports2018

The de novo design of a biocompatible and functional integral membrane protein using minimal sequence complexity.

Christophe J Lalaurie, Virginie Dufour, Anna Meletiou, Sarah Ratcliffe, Abigail Harland, Olivia Wilson, Chiratchaya Vamasiri, Deborah K Shoemark, Christopher Williams, Christopher J Arthur and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Cellular production of a de novo membrane cytochrome.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Dissecting the stability determinants of a challenging de novo protein fold using massively parallel design and experimentation.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  4. Review
  5. Article
  6. Designing minimalist membrane proteins.Biochemical Society transactions · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Christophe J LalaurieSchool of Biochemistry, University of Bristol, Bristol, UK.
Virginie DufourSchool of Biochemistry, University of Bristol, Bristol, UK.
Anna MeletiouSchool of Biochemistry, University of Bristol, Bristol, UK.
Sarah RatcliffeSchool of Biochemistry, University of Bristol, Bristol, UK.
Abigail HarlandSchool of Biochemistry, University of Bristol, Bristol, UK.
Olivia WilsonSchool of Biochemistry, University of Bristol, Bristol, UK.
Chiratchaya VamasiriSchool of Biochemistry, University of Bristol, Bristol, UK.
Deborah K ShoemarkSchool of Biochemistry, University of Bristol, Bristol, UK.
Christopher WilliamsSchool of Chemistry, University of Bristol, Bristol, UK.
Christopher J ArthurSchool of Chemistry, University of Bristol, Bristol, UK.
Richard B SessionsSchool of Biochemistry, University of Bristol, Bristol, UK.
Matthew P CrumpSchool of Chemistry, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-7868-5818
J L Ross AndersonSchool of Biochemistry, University of Bristol, Bristol, UK.
Paul CurnowSchool of Biochemistry, University of Bristol, Bristol, UK. p.curnow@bristol.ac.uk.
University of Bristol · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L01386X/1Biotechnology and Biological Sciences Research Council (BBSRC) BB/L01386X/1
6 · The paper itself

Abstract

The de novo design of integral membrane proteins remains a major challenge in protein chemistry. Here, we describe the bottom-up design of a genetically-encoded synthetic membrane protein comprising only four amino acids (L, S, G and W) in the transmembrane domains. This artificial sequence, which we call REAMP for recombinantly expressed artificial membrane protein, is a single chain of 133 residues arranged into four antiparallel membrane-spanning α-helices. REAMP was overexpressed in Escherichia coli and localized to the cytoplasmic membrane with the intended transmembrane topology. Recombinant REAMP could be extracted from the cell membrane in detergent micelles and was robust and stable in vitro, containing helical secondary structure consistent with the original design. Engineered mono- and bis-histidine residues in the membrane domain of REAMP were able to coordinate heme in vitro, in a manner reminiscent of natural b-type cytochromes. This binding shifted the electrochemical potential of the cofactor, producing a synthetic hemoprotein capable of nascent redox catalysis. These results show that a highly reduced set of amino acids is sufficient to mimic some key properties of natural proteins, and that cellular biosynthesis is a viable route for the production of minimal de novo membrane sequences.

Indexed as

Gene ExpressionCell MembraneEscherichia coliHemeMembrane ProteinsProtein BindingProtein ConformationProtein StabilityRecombinant ProteinsHemeMembrane ProteinsRecombinant Proteins

Identifiers

PMID30275547
PMCPMC6167376
OpenAlexW2888383240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.